Mobile van study of a long-acting HIV prevention shot
Treatments studied
Part of Infections clinical trials.
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You speak English or Spanish.
- You are HIV negative (confirmed by a rapid test on the day you join).
- You are at risk for HIV (for example, you want PrEP or your clinician thinks you may benefit).
- You are willing to stop any other PrEP medication you are currently taking.
- You can be reached by a UCLA mobile health van in Los Angeles County.
- Pregnant or breastfeeding women can join after discussing risks and benefits with the doctor.
- Your BMI must be under 35 (about 77 pounds or less is not allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
This study tests a new approach to help men at risk for HIV stay healthy by providing access to PrEP through a mobile app. The goal is to see if the program helps men start and stay on PrEP compared to standard care.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
This trial tests a nurse-run program that makes it easier to get long-acting injectable PrEP (cabotegravir) for HIV prevention. It aims to see if nurses can start and provide this shot quickly at your regular clinic visits.
This study follows people taking a new long-acting HIV prevention injection called LA CAB (cabotegravir). Researchers want to understand how well it works, how people use it, and what side effects occur in real-world NHS clinics.
Hear when a new HIV Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.